DCM
ESPR

Discovery Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Discovery Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-234,715
Closed -$9.2M – 59
2018
Q2 		$9.2M Buy
234,715
+35,800
+18% +$1.81M 0.5% 38
2018
Q1 		$14.4M Sell
198,915
-276,260
-58% -$20.3M 0.5% 40
2017
Q4 		$31.3M Sell
475,175
-307,884
-39% -$16.6M 0.97% 36
2017
Q3 		$39.2M Sell
783,059
-182,000
-19% -$8.78M 0.94% 36
2017
Q2 		$44.7M Buy
965,059
+583,529
+153% +$21.5M 1.08% 29
2017
Q1 		$13.5M Sell
381,530
-660,516
-63% -$15.1M 0.25% 74
2016
Q4 		$13M Sell
1,042,046
-7,954
-0.8% -$94.7K 0.22% 77
2016
Q3 		$14.5M Hold
1,050,000
– – 0.31% 57
2016
Q2 		$10.4M Buy
1,050,000
+243,895
+30% +$4.04M 0.24% 61
2016
Q1 		$13.6M Buy
806,105
+138,573
+21% +$2.23M 0.2% 71
2015
Q4 		$14.9M Buy
667,532
+143,332
+27% +$3.62M 0.18% 77
2015
Q3 		$12.4M Buy
+524,200
New +$32.9M 0.14% 88

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Discovery Capital Management's ESPR Position: Q3 2018 in Review

Discovery Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 234,715 shares — an estimated $9.2M sold.

Discovery Capital Management first reported a position in ESPR in Q3 2015 and held it in 12 quarters. The position peaked at $44.7M in Q2 2017. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • Discovery Capital Management reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Discovery Capital Management sold 234,715 Esperion Therapeutics shares in Q3 2018, an estimated $9.2M.
  • Discovery Capital Management first reported a position in Esperion Therapeutics in Q3 2015 and held it in 12 quarters.
  • Discovery Capital Management's Esperion Therapeutics position peaked at $44.7M in Q2 2017.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Discovery Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.